---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-004548"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:27:32.885608+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Positive RCT results for CytoSorb in heart transplant show reduced organ failure and shorter ICU stays

## Summary
- Vasoplegic syndrome rate 20% vs 48% control (p=0.028); odds 6.4× lower in CytoSorb group.
- Acute kidney injury 36.7% vs 76.0% control (p=0.004); no renal replacement therapy needed (0% vs 16%).
- Median ICU stay 8.5 days vs 12 days control (p=0.022); mechanical ventilation 25 vs 65 hours.
- No removal of anti-rejection drug mycophenolic acid and no device-related adverse events reported.
- Study published in European Society of Cardiology journal ESC Heart Failure.

## SEC filing metadata
- accession: 0001104659-24-004548
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924004548/0001104659-24-004548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924004548/tm243541-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-004548
- JSON: https://secwatch.observer/filing/0001104659-24-004548.json
- Plain text: https://secwatch.observer/filing/0001104659-24-004548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.